Allogeneic refers to cells or tissues that are genetically diverse and thus not perfectly immunologically compatible. Allogenic transplants are so called because the transplanted tissue comes from another individual. The closest match available would give the greatest chance of a successful transplant.
With iPSCs continuing to emerge as an important source of starting materials for cell therapy developers, it is crucial to tackle key remaining challenges relating to cell culture scalabilit...
Cell-based therapies are advanced medical treatments for cancers and other diseases. Autologous and allogeneic cell therapies use immune cells from either a patient or from healthy donor sam...
Natural killer (NK) cells, immune cells with an innate ability to recognize and eliminate cancer cells, have emerged as attractive effectors in immunotherapy, owing in large part to their ab...
Inefficient knock-in of transgene cargos limits the potential of cell-based medicines. In this study, we used a CRISPR nuclease that targets a site within an exon of an essential gene and de...
Cell-based immunotherapy has become the new-generation cancer medicine, and “off-the-shelf” cell products that can be manufactured at large scale and distributed readily to treat...
The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...
Immune cell therapies hold tremendous potential in the treatment of cancer. Among immune cells, natural killer (NK) cells have a powerful innate ability to recognize and eliminate tumor cell...
Date: January 25, 2023 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CET) Allogeneic hematopoietic cell transplantation (HCT) is curative for hematological diseases; however, is also associated...
Human Allogeneic Liver-derived Progenitor Cells (HALPC; HepaStemTM) are an advanced therapy medicinal product composed of medicinal signaling cells derived and expanded from healthy human li...
Date: August 26, 2021 Time: 8:00am (PDT), 11:00am (EDT) My translational research program focuses on approaches to enhance the natural killer (NK) cell response to cancer, with an emphasis o...
Though tumor targeting using chimeric receptors (CAR) engineered to bind tumor-associated surface proteins such as CD19 in B cells have demonstrated remarkable efficacy in cancer, this thera...
Though AsCas12a fills a crucial gap in the current genome editing toolbox, it exhibits relatively poor editing efficiency, restricting its overall utility. In collaboration with Integrated D...
T-cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor-infiltrating lymphocytes and peripheral...
Engineered cell therapy is an emerging field of science to target and treat cancer. Current strategies include utilizing immune cells such as T cells, NK cells and Macrophages or other cells...
Cell encapsulation within semi-permeable devices represents a local immunoisolation strategy for cell-based therapies without the need for systemic immunosuppression. The encapsulation syste...
DATE: January 27, 2021 TIME: 9am PST Well-timed interaction of correctly functioning maternal immune cells is essential to facilitate healthy placenta formation, as the uterine immune enviro...
Date: September 28, 2020 Time: 5:00pm (PDT), 8:00am (HKT), 9:00am (JST) Although there have been dramatic advances in the field of single-cell sequencing, current methods cannot be applied t...
DATE: June 23, 2020 TIME: 6:00 am PDT, 9:00 am EDT In this webinar for scientists and researchers, Rama Shivakumar, a senior scientist at MaxCyte Inc., will highlight powerful case studies t...
DATE: March 26, 2020 TIME: 9:00am PST, 12:00pm EST Growing demand for precision therapy and the recent successes with CAR-T cells for cancer treatment...
DATE: February 27, 2019TIME: 8:00am PST Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture...
In contrast to autologous cell therapies, allogeneic therapies do not require collection of starting material from patients and could; be manufactured in larger batches, be made available &ld...
DATE: September 13, 2017 TIME: 9:00AM SGT 12:00PM AEDTORDATE: September 12, 2017TIME: 6:00PM PDT To transform the promises of cell-based therapies int...
With iPSCs continuing to emerge as an important source of starting materials for cell therapy developers, it is crucial to tackle key remaining challenges relating to cell culture scalabilit...
Cell-based therapies are advanced medical treatments for cancers and other diseases. Autologous and allogeneic cell therapies use immune cells from either a patient or from healthy donor sam...
Natural killer (NK) cells, immune cells with an innate ability to recognize and eliminate cancer cells, have emerged as attractive effectors in immunotherapy, owing in large part to their ab...
Inefficient knock-in of transgene cargos limits the potential of cell-based medicines. In this study, we used a CRISPR nuclease that targets a site within an exon of an essential gene and de...
Cell-based immunotherapy has become the new-generation cancer medicine, and “off-the-shelf” cell products that can be manufactured at large scale and distributed readily to treat...
The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...
Immune cell therapies hold tremendous potential in the treatment of cancer. Among immune cells, natural killer (NK) cells have a powerful innate ability to recognize and eliminate tumor cell...
Date: January 25, 2023 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CET) Allogeneic hematopoietic cell transplantation (HCT) is curative for hematological diseases; however, is also associated...
Human Allogeneic Liver-derived Progenitor Cells (HALPC; HepaStemTM) are an advanced therapy medicinal product composed of medicinal signaling cells derived and expanded from healthy human li...
Date: August 26, 2021 Time: 8:00am (PDT), 11:00am (EDT) My translational research program focuses on approaches to enhance the natural killer (NK) cell response to cancer, with an emphasis o...
Though tumor targeting using chimeric receptors (CAR) engineered to bind tumor-associated surface proteins such as CD19 in B cells have demonstrated remarkable efficacy in cancer, this thera...
Though AsCas12a fills a crucial gap in the current genome editing toolbox, it exhibits relatively poor editing efficiency, restricting its overall utility. In collaboration with Integrated D...
T-cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor-infiltrating lymphocytes and peripheral...
Engineered cell therapy is an emerging field of science to target and treat cancer. Current strategies include utilizing immune cells such as T cells, NK cells and Macrophages or other cells...
Cell encapsulation within semi-permeable devices represents a local immunoisolation strategy for cell-based therapies without the need for systemic immunosuppression. The encapsulation syste...
DATE: January 27, 2021 TIME: 9am PST Well-timed interaction of correctly functioning maternal immune cells is essential to facilitate healthy placenta formation, as the uterine immune enviro...
Date: September 28, 2020 Time: 5:00pm (PDT), 8:00am (HKT), 9:00am (JST) Although there have been dramatic advances in the field of single-cell sequencing, current methods cannot be applied t...
DATE: June 23, 2020 TIME: 6:00 am PDT, 9:00 am EDT In this webinar for scientists and researchers, Rama Shivakumar, a senior scientist at MaxCyte Inc., will highlight powerful case studies t...
DATE: March 26, 2020 TIME: 9:00am PST, 12:00pm EST Growing demand for precision therapy and the recent successes with CAR-T cells for cancer treatment...
DATE: February 27, 2019TIME: 8:00am PST Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture...
In contrast to autologous cell therapies, allogeneic therapies do not require collection of starting material from patients and could; be manufactured in larger batches, be made available &ld...
DATE: September 13, 2017 TIME: 9:00AM SGT 12:00PM AEDTORDATE: September 12, 2017TIME: 6:00PM PDT To transform the promises of cell-based therapies int...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
